Consequently, breast cancers with loss of function mutations in the JNK pathway kinases MEKK1 or MKK4 should benefit from MEK inhibitor therapy, a hypothesis successfully confirmed in patient derived xenografts [76]. This evidence concerns the gene MAP2K7 and breast cancer.